Table 1 Characteristics of ACS patients stratified by management strategy
Characteristic | Medical management n=49,652 | PCI n=56,358 | CABG n=8,132 | p value |
|---|---|---|---|---|
Age* | 75.71 ± 6.50 | 75.71 ± 6.94 | 74.11 ± 5.63 | <.001 |
Male sex (%male) | 30,742 (61.9%) | 35,137 (62.3%) | 5973 (73.5%) | <.001 |
Current smoker | 6521 (13.1%) | 8010 (14.2%) | 1272 (15.6%) | NS |
Previous smoker | 17,301 (34.8%) | 16,532 (29.3%) | 2866 (35.2%) | <.001 |
COPD | 5276 (10.6%) | 4552 (8.1%) | 598 (7.4%) | <.001 |
CVD | 5723 (11.5%) | 5240 (9.3%) | 809 (9.9%) | <.001 |
CHF | 7157 (14.4%) | 4962 (8.8%) | 812 (10.0%) | <.001 |
Diabetes | 18,193 (36.6%) | 16,737 (29.7%) | 2855 (35.1%) | <.001 |
Hyperlipidemia | 37,018 (74.6%) | 34,964 (62.0%) | 5418 (66.6%) | <.001 |
Hypertension | 39,566 (79.7%) | 40,309 (71.5%) | 6025 (74.1%) | <.001 |
History of MI | 18,988 (38.2%) | 15,950 (28.3%) | 1947 (23.9%) | <.001 |
PVD | 5583 (11.2%) | 4,533 (8.0%) | 839 (10.3%) | <.001 |
Renal disease | 261 (0.5%) | 215 (0.4%) | 31 (0.4%) | NS |
Previous CABG | 10,643 (21.4%) | 8042 (14.3%) | 251 (3.1%) | <.001 |
Previous PCI | 11,722 (23.6%) | 12,284 (21.8%) | 977 (12.0%) | <.001 |
Previous antithrombotic | ||||
 Dabigatran | 744 (1.5%) | 630 (1.1%) | 58 (0.1%) | <.001 |
 Apixaban | 779 (1.6%) | 795 (1.4%) | 66 (0.8%) | <.001 |
 Rivaroxaban | 992 (2.0%) | 1,156 (2.1%) | 116 (1.4%) | <.001 |
 Warfarin | 4,894 (9.9%) | 3,700 (6.6%) | 396 (4.9%) | <.001 |
 Prasugrel | 21 (0.0%) | 36 (0.1%) | 0 (0.0%) | NS |
 Clopidogrel | 11,575 (23.3%) | 10,614 (18.8%) | 1029 (12.7%) | <.001 |
 Ticagrelor | 589 (1.2%) | 992 (1.8%) | 45 (0.6%) | <.001 |